20 results match your criteria Substance-Induced Mood Disorders Depression and Mania

  • Page 1 of 1

Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.

Eur J Endocrinol 2019 Jan;180(1):31-40

Division of Endocrinology, Gerontology and Metabolism, Department of Medicine and Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.

Background Dopamine agonists (DAs) are the main treatment for patients with hyperprolactinemia and prolactinomas. Recently, an increasing number of reports emphasized DAs' psychological side effects, either de novo or as exacerbations of prior psychiatric disease. Methods Review of prospective and retrospective studies (PubMed 1976, September 2018) evaluating the psychological profile of DA-treated patients with hyperprolactinemia and prolactinomas. Read More

View Article and Full-Text PDF
January 2019

Isotretinoin: the ups are just as troubling as the downs.

G Ital Dermatol Venereol 2018 Aug 18;153(4):535-539. Epub 2018 Apr 18.

Department of Psychiatry, Dell Medical School, University of Texas at Austin, Austin, TX, USA -

Introduction: Isotretinoin, previously marketed as Accutane®, is an oral retinoid medication that is used to treat acne and other cutaneous disorders. Although the data is conflicting, previous reports suggest a causal relationship between isotretinoin and depression. When reviewing these previous reports, many patients who were diagnosed as "depressed" did not undergo a thorough psychiatric evaluation and/or were not diagnosed according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM). Read More

View Article and Full-Text PDF

Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users.

Psychiatry Res 2016 Apr 18;238:166-171. Epub 2016 Feb 18.

Turning Point, Eastern Health and Monash University, Melbourne, Australia.

This study examined correlates of transient versus persistent psychotic symptoms among people dependent on methamphetamine. A longitudinal prospective cohort study of dependent methamphetamine users who did not meet DSM-IV criteria for lifetime schizophrenia or mania. Four non-contiguous one-month observation periods were used to identify participants who had a) no psychotic symptoms, (n=110); (b) psychotic symptoms only when using methamphetamine (transient psychotic symptoms, n=85); and, (c) psychotic symptoms both when using methamphetamine and when abstaining from methamphetamine (persistent psychotic symptoms, n=37). Read More

View Article and Full-Text PDF

Use of ECT in Nepal: A One Year Study From the Country's Largest Psychiatric Facility.

J Clin Diagn Res 2016 Feb 1;10(2):VC01-VC04. Epub 2016 Feb 1.

Nursing Incharge, Department of Psychiatry, UCMS , Bhairahawa, Nepal .

Introduction: Electro-Convulsive Therapy (ECT) refers to the electrical stimulation of the brain to produce seizures for therapeutic purpose. Since the development of ECT, it's use has been consistent. Inspite of the common use, data pertaining to the use of ECT in Nepal is lacking. Read More

View Article and Full-Text PDF
February 2016

Do clinical trials of treatment of alcohol dependence adequately enroll participants with co-occurring independent mood and anxiety disorders? An analysis of data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).

J Clin Psychiatry 2014 Mar;75(3):231-7

Hôpital Corentin-Celton, 4 parvis Corentin Celton, 92130 Issy-les-Moulineaux, France

Background: In the care of alcohol-dependent patients, co-occurring independent (ie, not substance-induced) mood and anxiety disorders present a significant challenge. Clinical trials of alcohol dependence treatment could help clinicians meet this challenge, but only if they enroll such complex patients. This study examined whether such individuals are likely to be included in alcohol dependence treatment trials under typical eligibility criteria. Read More

View Article and Full-Text PDF

[Mood disorder after malaria prophylaxis with mefloquine (two case reports)].

Encephale 2011 Oct 25;37(5):393-6. Epub 2011 Mar 25.

Service de psychiatrie, hôpital militaire Avicenne, Marrakech, Maroc.

Introduction: Mefloquine (Lariam) is the drug of choice as malaria prophylaxis for travel to chloroquine-resistant areas. Severe neuropsychiatric side effects are rare. We report two clinical cases of mood disorders: mania and a major depressive episode with psychotic characteristics in two patients with mefloquine antimalarial prophylaxis. Read More

View Article and Full-Text PDF
October 2011

A comparison of the symptoms and short-term clinical course in inpatients with substance-induced psychosis and primary psychosis.

J Subst Abuse Treat 2011 Jan 22;40(1):95-101. Epub 2010 Sep 22.

Griffith University, Brisbane, 4111, Queensland, Australia.

Relatively little is known about the clinical course of symptoms in patients with a substance-induced psychosis (SIP) compared with those with a primary psychotic disorder (PPD). In this study, symptoms associated with psychosis were monitored across admission in two groups of patients: those with SIP (amphetamines or cannabis; n = 47) and those with PPD (n = 51). Sixty-two percent of patients were first admissions, 23% had one previous admission, and a further 14% had had two previous admissions. Read More

View Article and Full-Text PDF
January 2011

Managing the neuropsychiatric complications of hepatitis C treatment.

Br J Hosp Med (Lond) 2007 Oct;68(10):520-5

Department of Psychiatry, Centre for Addiction and Mental Health, Toronto, ON.

Interferon-alpha is the mainstay of hepatitis C treatment and has been linked to several neuropsychiatric complications, including depression, anxiety, mania, psychosis and cognitive changes. This article reviews the management of neuropsychiatric adverse effects and the risks of interferon-alpha treatment to psychiatric patients. Read More

View Article and Full-Text PDF
October 2007

Pramipexole in psychiatry: a systematic review of the literature.

Chris B Aiken

J Clin Psychiatry 2007 Aug;68(8):1230-6

Department of Psychiatry, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Objective: To assess the risks and benefits of pramipexole in psychiatric populations.

Data Sources: A PubMed search was performed using the keywords pramipexole and ropinirole, which identified 500 articles.

Study Selection: All clinical studies in psychiatric populations were included in the primary review (24 articles). Read More

View Article and Full-Text PDF

Neuropsychiatric complications of interferons: classification, neurochemical bases, and management.

Ann Clin Psychiatry 2007 Apr-Jun;19(2):113-23

Department of Neuropsychiatry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430-8103, USA.

Background: Recombinant interferons are widely used for a number of serious illnesses. However, their use is sometimes associated with severe and disabling neuropsychiatric side effects.

Methods: A MEDLINE search identified pertinent laboratory investigations, case reports, clinical studies and letters published between 1983 and 2004 in the English language journals. Read More

View Article and Full-Text PDF
October 2007

[Psychiatric complications of corticoid therapy in the elderly over 65 years of age treated for Horton disease].

Rev Med Interne 2002 Oct;23(10):828-33

Service de médecine interne A, hôpital Claude-Huriez, CHRU, 59037 Lille, France.

Objectives: To analyse steroid psychiatric related complications in aged (> 65 years old) with temporal arteritis (TA).

Methods: Retrospective cohort study.

Patients: In a cohort of 126 elderly patients with a diagnosis of TA and followed with a mean period of 64 months, clinical and biological presentations, outcome and corticoid adverse effects were recorded throughout the follow-up period. Read More

View Article and Full-Text PDF
October 2002

[Alpha-interferon and mental disorders].

Encephale 2001 Jul-Aug;27(4):308-17

Service de Psychiatrie Adulte, CHRU de Lille, 6, rue du Professeur Laguesse, 59037 Lille.

Unlabelled: The interferon alpha stands as a reference both in oncology and virology. But its efficiency is limited by frequent somatic as well as neuropsychic side effects. As a matter of fact, the reduction or the ending of a chemotherapy treatment come chiefly from the psychiatric complications caused by the use of interferon. Read More

View Article and Full-Text PDF
December 2001

Psychoses associated with thyrotoxicosis - 'thyrotoxic psychosis.' A report of 18 cases, with statistical analysis of incidence.

Eur J Endocrinol 2000 May;142(5):438-44

Department of Nuclear Medicine, Christchurch Hospital, Christchurch, New Zealand.

Objective: To report a series of newly diagnosed thyrotoxic patients with concurrent acute psychosis, and to assess the association between the two disorders.

Design: Retrospective study of thyrotoxic patients with associated psychosis ('thyrotoxic psychosis'; TP) requiring inpatient psychiatric care. New Zealand thyrotoxicosis annual incidence figures and first psychiatric admission rates for affective psychosis were utilised to statistically assess the co-occurrence of thyrotoxicosis and affective psychosis. Read More

View Article and Full-Text PDF

The psychiatric side effects of corticosteroids.

Ann Allergy Asthma Immunol 1999 Dec;83(6 Pt 1):495-503; quiz 503-4

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas 75235-9101, USA.

Learning Objectives: Readers will learn the importance of psychiatric symptomatology with corticosteroid drug therapy, especially when combined with other medications.

Data Sources: A brief history of corticosteroid use over the last five decades was complied utilizing MEDLINE and PSYCHOINFO as sources of information which include peer-reviewed research articles, case studies, and relevant reviews in English.

Conclusion: Corticosteroids are routinely prescribed for a variety of allergic and immunologic illnesses. Read More

View Article and Full-Text PDF
December 1999

Mood symptoms during corticosteroid therapy: a review.

E S Brown T Suppes

Harv Rev Psychiatry 1998 Jan-Feb;5(5):239-46

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas 75235-9070, USA.

Corticosteroids such as prednisone are commonly prescribed for a variety of illnesses mediated by the immune system. This paper reviews the available literature on mood symptoms during corticosteroid treatment. Few studies have used well-recognized measures of symptoms or clearly defined diagnostic criteria to characterize such mood changes. Read More

View Article and Full-Text PDF

Antidepressants and mania.

D Healy

Am J Psychiatry 1988 Jul;145(7):906-7

View Article and Full-Text PDF

Two case reports of trazodone-induced mania.

M Warren P A Bick

Am J Psychiatry 1984 Sep;141(9):1103-4

Two unipolar depressed patients developed manic symptoms when treated with trazodone. The symptoms resolved when the drug was discontinued. The authors believe these to be the first two cases of such a reaction reported in the literature. Read More

View Article and Full-Text PDF
September 1984
  • Page 1 of 1